Literature DB >> 23034915

Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings.

Fanny Mochel1, Raphael Schiffmann, Marjan E Steenweg, Hasan O Akman, Mary Wallace, Frédéric Sedel, Pascal Laforêt, Richard Levy, J Michael Powers, Sophie Demeret, Thierry Maisonobe, Roseline Froissart, Bruno Barcelos Da Nobrega, Brent L Fogel, Marvin R Natowicz, Catherine Lubetzki, Alexandra Durr, Alexis Brice, Hanna Rosenmann, Varda Barash, Or Kakhlon, J Moshe Gomori, Marjo S van der Knaap, Alexander Lossos.   

Abstract

OBJECTIVE: Adult polyglucosan body disease (APBD) is an autosomal recessive leukodystrophy characterized by neurogenic bladder, progressive spastic gait, and peripheral neuropathy. Polyglucosan bodies accumulate in the central and peripheral nervous systems and are often associated with glycogen branching enzyme (GBE) deficiency. To improve clinical diagnosis and enable future evaluation of therapeutic strategies, we conducted a multinational study of the natural history and imaging features of APBD.
METHODS: We gathered clinical, biochemical, and molecular findings in 50 APBD patients with GBE deficiency from Israel, the United States, France, and the Netherlands. Brain and spine magnetic resonance images were reviewed in 44 patients.
RESULTS: The most common clinical findings were neurogenic bladder (100%), spastic paraplegia with vibration loss (90%), and axonal neuropathy (90%). The median age was 51 years for the onset of neurogenic bladder symptoms, 63 years for wheelchair dependence, and 70 years for death. As the disease progressed, mild cognitive decline may have affected up to half of the patients. Neuroimaging showed hyperintense white matter abnormalities on T2 and fluid attenuated inversion recovery sequences predominantly in the periventricular regions, the posterior limb of the internal capsule, the external capsule, and the pyramidal tracts and medial lemniscus of the pons and medulla. Atrophy of the medulla and spine was universal. p.Y329S was the most common GBE1 mutation, present as a single heterozygous (28%) or homozygous (48%) mutation.
INTERPRETATION: APBD with GBE deficiency, with occasional exceptions, is a clinically homogenous disorder that should be suspected in patients with adult onset leukodystrophy or spastic paraplegia with early onset of urinary symptoms and spinal atrophy.
Copyright © 2012 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23034915      PMCID: PMC4329926          DOI: 10.1002/ana.23598

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  33 in total

Review 1.  Congenital form of glycogen storage disease type IV: a case report and a review of the literature.

Authors:  Keinchi Maruyama; Tomoko Suzuki; Takenobu Koizumi; Hideo Sugie; Tokiko Fukuda; Masataka Ito; Junko Hirato
Journal:  Pediatr Int       Date:  2004-08       Impact factor: 1.524

2.  Spinal cord MRI in adult polyglucosan body disease.

Authors:  C Negishi; G Sze
Journal:  J Comput Assist Tomogr       Date:  1992 Sep-Oct       Impact factor: 1.826

3.  A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora's disease and normal ageing.

Authors:  Y Robitaille; S Carpenter; G Karpati; S D DiMauro
Journal:  Brain       Date:  1980-06       Impact factor: 13.501

Review 4.  Polyglucosan body disease.

Authors:  M S Cafferty; R E Lovelace; A P Hays; S Servidei; S Dimauro; L P Rowland
Journal:  Muscle Nerve       Date:  1991-02       Impact factor: 3.217

5.  Hereditary branching enzyme dysfunction in adult polyglucosan body disease: a possible metabolic cause in two patients.

Authors:  A Lossos; V Barash; D Soffer; Z Argov; M Gomori; Z Ben-Nariah; O Abramsky; I Steiner
Journal:  Ann Neurol       Date:  1991-11       Impact factor: 10.422

6.  Adult polyglucosan body disease: the diagnostic value of axilla skin biopsy.

Authors:  H L Busard; A A Gabreëls-Festen; W O Renier; F J Gabreëls; E M Joosten; M A van 't Hof; J B Rensing
Journal:  Ann Neurol       Date:  1991-04       Impact factor: 10.422

7.  Adult polyglucosan body disease: a postmortem correlation study.

Authors:  E Sindern; F Ziemssen; T Ziemssen; T Podskarbi; Y Shin; F Brasch; K M Müller; J M Schröder; J-P Malin; M Vorgerd
Journal:  Neurology       Date:  2003-07-22       Impact factor: 9.910

8.  Adult polyglucosan body disease: case description of an expanding genetic and clinical syndrome.

Authors:  Christopher J Klein; Christopher J Boes; John E Chapin; Christopher D Lynch; Norbert G Campeau; P James B Dyck; Peter J Dyck
Journal:  Muscle Nerve       Date:  2004-02       Impact factor: 3.217

9.  Fatal infantile neuromuscular presentation of glycogen storage disease type IV.

Authors:  Stacey K H Tay; Hasan O Akman; Wendy K Chung; Michael G Pike; Francesco Muntoni; Arthur P Hays; Sara Shanske; Stephanie J Valberg; James R Mickelson; Kurenai Tanji; Salvatore DiMauro
Journal:  Neuromuscul Disord       Date:  2004-04       Impact factor: 4.296

10.  Adult polyglucosan body disease (APBD).

Authors:  F Gray; R Gherardi; A Marshall; I Janota; J Poirier
Journal:  J Neuropathol Exp Neurol       Date:  1988-07       Impact factor: 3.685

View more
  36 in total

Review 1.  An updated diagnostic approach to subtype definition of vascular parkinsonism - Recommendations from an expert working group.

Authors:  Ivan Rektor; Nicolaas I Bohnen; Amos D Korczyn; Viktoria Gryb; Hrishikesh Kumar; Milica G Kramberger; Frank-Erik de Leeuw; Zvezdan Pirtošek; Irena Rektorová; Ilana Schlesinger; Jaroslaw Slawek; Peter Valkovič; Branislav Veselý
Journal:  Parkinsonism Relat Disord       Date:  2017-12-29       Impact factor: 4.891

2.  Late-onset polyglucosan body myopathy in five patients with a homozygous mutation in GYG1.

Authors:  H Orhan Akman; Yavuz Aykit; Ozge Ceren Amuk; Edoardo Malfatti; Norma B Romero; Maria Antonietta Maioli; Rachele Piras; Salvatore DiMauro; Gianni Marrosu
Journal:  Neuromuscul Disord       Date:  2015-11-10       Impact factor: 4.296

3.  Skeletal Muscle Glycogen Chain Length Correlates with Insolubility in Mouse Models of Polyglucosan-Associated Neurodegenerative Diseases.

Authors:  Mitchell A Sullivan; Silvia Nitschke; Evan P Skwara; Peixiang Wang; Xiaochu Zhao; Xiao S Pan; Erin E Chown; Travis Wang; Ami M Perri; Jennifer P Y Lee; Francisco Vilaplana; Berge A Minassian; Felix Nitschke
Journal:  Cell Rep       Date:  2019-04-30       Impact factor: 9.423

Review 4.  Posterior fossa involvement in the diagnosis of adult-onset inherited leukoencephalopathies.

Authors:  Xavier Ayrignac; Clemence Boutiere; Clarisse Carra-Dalliere; Pierre Labauge
Journal:  J Neurol       Date:  2016-04-28       Impact factor: 4.849

5.  A novel image-based high-throughput screening assay discovers therapeutic candidates for adult polyglucosan body disease.

Authors:  Leonardo J Solmesky; Netaly Khazanov; Hanoch Senderowitz; Peixiang Wang; Berge A Minassian; Igor M Ferreira; Wyatt W Yue; Alexander Lossos; Miguel Weil; Or Kakhlon
Journal:  Biochem J       Date:  2017-09-28       Impact factor: 3.857

6.  Adult polyglucosan body disease-an atypical compound heterozygous with a novel GBE1 mutation.

Authors:  Andreia Carvalho; Joana Nunes; Ricardo Taipa; Manuel Melo Pires; Jorge Pinto Basto; Pedro Barros
Journal:  Neurol Sci       Date:  2021-01-31       Impact factor: 3.307

7.  Cognitive profile of patients with glycogen storage disease type III: a clinical description of seven cases.

Authors:  Claire-Cécile Michon; Marcela Gargiulo; Valérie Hahn-Barma; François Petit; Aleksandra Nadaj-Pakleza; Ariane Herson; Bruno Eymard; Philippe Labrune; Pascal Laforet
Journal:  J Inherit Metab Dis       Date:  2014-11-12       Impact factor: 4.982

8.  A novel mouse model that recapitulates adult-onset glycogenosis type 4.

Authors:  H Orhan Akman; Valentina Emmanuele; Yasemin Gülcan Kurt; Bülent Kurt; Tatiana Sheiko; Salvatore DiMauro; William J Craigen
Journal:  Hum Mol Genet       Date:  2015-09-18       Impact factor: 6.150

9.  A double-blind, placebo-controlled trial of triheptanoin in adult polyglucosan body disease and open-label, long-term outcome.

Authors:  Raphael Schiffmann; Mary E Wallace; Daisy Rinaldi; Isabelle Ledoux; Marie-Pierre Luton; Scott Coleman; H Orhan Akman; Karine Martin; Jean-Yves Hogrel; Derek Blankenship; Jacob Turner; Fanny Mochel
Journal:  J Inherit Metab Dis       Date:  2017-11-06       Impact factor: 4.982

10.  A Modified Enzymatic Method for Measurement of Glycogen Content in Glycogen Storage Disease Type IV.

Authors:  Haiqing Yi; Quan Zhang; Chunyu Yang; Priya S Kishnani; Baodong Sun
Journal:  JIMD Rep       Date:  2016-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.